Poolbeg Pharma PLC




Biotechnology & Medical Research

Market Closed - London S.E. 09:05:02 21/06/2024 pm IST 5-day change 1st Jan Change
12.15 GBX -1.62% Intraday chart for Poolbeg Pharma PLC -12.59% +34.25%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Poolbeg Pharma Secures Full Patent in US for Immunomodulator II MT
Poolbeg Pharma celebrates full patent approval for Immunomodulator II AN
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application CI
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics MT
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down AN
Earnings Flash (POLB.L) POOLBEG PHARMA Posts FY23 Loss GBX-0.79 MT
Poolbeg Pharma PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake AN
Poolbeg Pharma plc Announces POLB 001 US Patent Update CI
Diversified Energy offers dividend alternative AN
Poolbeg Pharma's Nonexecutive Chair Transitions to Executive Role MT
Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman CI
Katoro Gold launches fundraising, eyes board shake-up AN
Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome CI
Poolbeg Pharma Therapy Shows Efficacy in Lowering Cancer Immunotherapy-induced Cytokine Release Syndrome MT
Poolbeg Pharma hails POLB 001'S potential to treat CRS AN
Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome CI
K3 Business says cash balances ahead of forecast AN
Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully CI
Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001 CI
Poolbeg Pharma plc Announces Directorate Changes CI
Poolbeg hails approval; EDX links with Thermo Fisher AN
Poolbeg Pharma appoints former Amryt executives to team AN
Poolbeg Pharma Names Business, Legal Chiefs MT
Poolbeg Pharma plc Announces Executive Appointments CI
Chart Poolbeg Pharma PLC
More charts
Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.
More about the company
Mean consensus
Number of Analysts
Last Close Price
0.1215 GBP
Average target price
0.21 GBP
Spread / Average Target

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. POLB Stock
  4. News Poolbeg Pharma PLC
  5. Poolbeg Pharma Secures Full Patent in US for Immunomodulator II